← Leaderboards
Stanley Perlman
University Of Iowa
$26,823,592
Attributed
$34,990,951
Total exposure
20
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$56,519,082 · 21
By mechanism
P01$30,387,445 · 11
R01$25,013,694 · 7
T32$641,102 · 1
R56$403,341 · 1
R03$73,500 · 1
Top collaborators
- Kyeong-Ok Chang11 shared
- William C Groutas11 shared
- Lanying Du5 shared
- Fang Li5 shared
- Yunjeong Kim2 shared
Most similar at University Of Iowa
Same institution · by research overlap
- John F Engelhardt$56,184,900
- Gregory Wu$6,631,705
- Joseph Zabner$29,014,505
- Ajai A Dandekar$51,424
- Jessica Erin Hall$137,020
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusPathogenesisBaseViralSars CoronavirusSevere Acute Respiratory SyndromeAnimalsFundingInfectionCellsVaccine DevelopmentProteinsVaccinesImmune ResponseMiddle East Respiratory Syndrome CoronavirusCell CommunicationLung DiseasesLungT Cell ResponseReceptorCoronavirus InfectionsMediatingPathogenicityKnock-In Mouse
Grant awards (120)
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses$759,331
R01 · FY2025 · AI
Small Molecule Protease Inhibitors against MERS-CoV and Coronaviruses of Pandemic Potential$733,730
R01 · FY2025 · AI
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2$731,337
R01 · FY2025 · AI
Olfactory and neurological manifestations of acute and post-acute murine COVID-19$636,357
R01 · FY2025 · AI · contact PI
Training in Molecular Virology, Viral Pathogenesis and Viral Vectors$145,008
T32 · FY2025 · AI · contact PI
Small Molecule Protease Inhibitors against MERS-CoV and Coronaviruses of Pandemic Potential$773,323
R01 · FY2024 · AI
Olfactory and neurological manifestations of acute and post-acute murine COVID-19$656,039
R01 · FY2024 · AI · contact PI
Training in Molecular Virology, Viral Pathogenesis and Viral Vectors$125,259
T32 · FY2024 · AI · contact PI
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses$759,331
R01 · FY2023 · AI
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2$735,037
R01 · FY2023 · AI
Training in Molecular Virology, Viral Pathogenesis and Viral Vectors$125,432
T32 · FY2023 · AI · contact PI
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses$759,731
R01 · FY2022 · AI
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2$735,037
R01 · FY2022 · AI
Small Molecule Protease Inhibitors against MERS-CoV$728,584
R01 · FY2022 · AI
Training in Molecular Virology, Viral Pathogenesis and Viral Vectors$126,067
T32 · FY2022 · AI · contact PI
PPG: SARS-CoV-host cell interactions and vaccine development$1,254,329
P01 · FY2021 · AI · contact PI
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2$774,037
R01 · FY2021 · AI
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses$766,055
R01 · FY2021 · AI
Small Molecule Protease Inhibitors against MERS-CoV$730,761
R01 · FY2021 · AI
Role of microglia in MHV-induced demyelination$326,546
R01 · FY2021 · NS · contact PI
Animal/Virology Core$296,783
P01 · FY2021 · AI · contact PI
Project-004$182,399
P01 · FY2021 · AI · contact PI
Training in Molecular Virology, Viral Pathogenesis and Viral Vectors$119,336
T32 · FY2021 · AI · contact PI
Administrative Core$88,798
P01 · FY2021 · AI · contact PI
Project 1$79,983
P01 · FY2021 · AI · contact PI
PPG: SARS-CoV-host cell interactions and vaccine development$1,254,329
P01 · FY2020 · AI · contact PI
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses$832,650
R01 · FY2020 · AI
Small Molecule Protease Inhibitors against MERS-CoV$732,873
R01 · FY2020 · AI
Role of eicosanoids in pathogenic human CoV infections$545,235
R01 · FY2020 · AI · contact PI
Role of microglia in MHV-induced demyelination$326,881
R01 · FY2020 · NS · contact PI
Animal/Virology Core$296,783
P01 · FY2020 · AI · contact PI
Project-004$182,399
P01 · FY2020 · AI · contact PI
Administrative Core$88,798
P01 · FY2020 · AI · contact PI
Project 1$79,983
P01 · FY2020 · AI · contact PI
PPG: SARS-CoV-host cell interactions and vaccine development$1,254,329
P01 · FY2019 · AI · contact PI
Small Molecule Protease Inhibitors against MERS-CoV$734,924
R01 · FY2019 · AI
Role of eicosanoids in pathogenic human CoV infections$545,235
R01 · FY2019 · AI · contact PI
Role of microglia in MHV-induced demyelination$327,201
R01 · FY2019 · NS · contact PI
Animal/Virology Core$296,782
P01 · FY2019 · AI · contact PI
Project 4$182,399
P01 · FY2019 · AI · contact PI
Administrative Core$88,799
P01 · FY2019 · AI · contact PI
Project 1$79,983
P01 · FY2019 · AI · contact PI
PPG: SARS-CoV-host cell interactions and vaccine development$1,254,329
P01 · FY2018 · AI · contact PI
Small Molecule Protease Inhibitors against MERS-CoV$775,916
R01 · FY2018 · AI
Role of eicosanoids in pathogenic human CoV infections$545,235
R01 · FY2018 · AI · contact PI
Role of microglia in MHV-induced demyelination$327,505
R01 · FY2018 · NS · contact PI
Animal/Virology Core$295,245
P01 · FY2018 · AI · contact PI
Project 4$198,358
P01 · FY2018 · AI · contact PI
Administrative Core$83,442
P01 · FY2018 · AI · contact PI
Project 1$81,728
P01 · FY2018 · AI · contact PI
PPG: SARS-CoV-host cell interactions and vaccine development$1,280,579
P01 · FY2017 · AI · contact PI
Role of eicosanoids in pathogenic human CoV infections$545,235
R01 · FY2017 · AI · contact PI
Role of microglia in MHV-induced demyelination$327,795
R01 · FY2017 · NS · contact PI
Animal/Virology Core$296,888
P01 · FY2017 · AI · contact PI
Project 4$195,438
P01 · FY2017 · AI · contact PI
Administrative Core$88,781
P01 · FY2017 · AI · contact PI
Project 1$79,982
P01 · FY2017 · AI · contact PI
Role of eicosanoids in pathogenic human CoV infections$545,235
R01 · FY2016 · AI · contact PI
Role of CD4 T cell response in MHV-induced demyelination$329,420
R01 · FY2016 · NS · contact PI
PPG: SARS-CoV-host cell interactions and vaccine development$1,595,795
P01 · FY2015 · AI · contact PI
Role of anti-SARS-CoV T cell response in pathogenesis$377,500
R01 · FY2015 · AI · contact PI
Role of anti-SARS-CoV T cell response in pathogenesis$337,768
P01 · FY2015 · AI · contact PI
Role of CD4 T cell response in MHV-induced demyelination$329,420
R01 · FY2015 · NS · contact PI
Animal Core$240,256
P01 · FY2015 · AI · contact PI
Administrative Core$102,904
P01 · FY2015 · AI · contact PI
PPG: SARS-CoV-host cell interactions and vaccine development$1,595,796
P01 · FY2014 · AI · contact PI
Role of anti-SARS-CoV T cell response in pathogenesis$377,500
R01 · FY2014 · AI · contact PI
Role of CD4 T cell response in MHV-induced demyelination$326,126
R01 · FY2014 · NS · contact PI
Role of anti-SARS-CoV T cell response in pathogenesis$324,460
P01 · FY2014 · AI · contact PI
Animal Core$226,803
P01 · FY2014 · AI · contact PI
Administrative Core$96,990
P01 · FY2014 · AI · contact PI
PPG: SARS-CoV-host cell interactions and vaccine development$1,605,748
P01 · FY2013 · AI · contact PI
Role of anti-SARS-CoV T cell response in pathogenesis$410,469
P01 · FY2013 · AI · contact PI
Role of anti-SARS-CoV T cell response in pathogenesis$354,850
R01 · FY2013 · AI · contact PI
Role of CD4 T cell response in MHV-induced demyelination$317,891
R01 · FY2013 · NS · contact PI
Animal Core$210,842
P01 · FY2013 · AI · contact PI
Administrative Core$91,100
P01 · FY2013 · AI · contact PI
PPG: SARS-CoV-host cell interactions and vaccine development$1,595,795
P01 · FY2012 · AI · contact PI
Role of anti-SARS-CoV T cell response in pathogenesis$377,500
R01 · FY2012 · AI · contact PI
Role of anti-SARS-CoV T cell response in pathogenesis$337,404
P01 · FY2012 · AI · contact PI
Role of CD4 T cell response in MHV-induced demyelination$329,420
R01 · FY2012 · NS · contact PI
Animal Core$219,700
P01 · FY2012 · AI · contact PI
Administrative Core$94,928
P01 · FY2012 · AI · contact PI
PPG: SARS-CoV-host cell interactions and vaccine development$1,599,714
P01 · FY2011 · AI · contact PI
Role of anti-SARS-CoV T cell response in pathogenesis$377,292
R01 · FY2011 · AI · contact PI
Role of anti-SARS-CoV T cell response in pathogenesis$315,415
P01 · FY2011 · AI · contact PI
Animal Core$226,203
P01 · FY2011 · AI · contact PI
Administrative Core$132,429
P01 · FY2011 · AI · contact PI
Role of CTL escape mutants in MHV-induced demyelination$354,485
R01 · FY2010 · NS · contact PI
A novel strategy for developing a SARS-CoV vaccine$403,341
R56 · FY2009 · AI · contact PI
Role of CTL escape mutants in MHV-induced demyelination$299,835
R01 · FY2009 · NS · contact PI
Role of CTL escape mutants in MHV-induced demyelination$42,305
R01 · FY2009 · NS · contact PI
PPG: HOST VIRUS INTERACTIONS IN HCoV-SARS INFECTIONS$1,443,819
P01 · FY2008 · AI · contact PI
Role of CTL escape mutants in MHV-induced demyelination$299,835
R01 · FY2008 · NS · contact PI
Development of Murine Model for SARS-CoV Pathogenesis$281,001
P01 · FY2008 · AI · contact PI
Core--Virology Facility$161,321
P01 · FY2008 · AI · contact PI
PPG: HOST VIRUS INTERACTIONS IN HCoV-SARS INFECTIONS$1,443,818
P01 · FY2007 · AI · contact PI
Role of CTL escape mutants in MHV-induced demyelination$299,835
R01 · FY2007 · NS · contact PI
Development of Murine Model for SARS-CoV Pathogenesis$281,001
P01 · FY2007 · AI · contact PI
Core--Virology Facility$161,325
P01 · FY2007 · AI · contact PI
PPG: HOST VIRUS INTERACTIONS IN HCoV-SARS INFECTIONS$1,445,380
P01 · FY2006 · AI · contact PI
Role of CTL escape mutants in MHV-induced demyelination$319,478
R01 · FY2006 · NS · contact PI
Development of Murine Model for SARS-CoV Pathogenesis$288,074
P01 · FY2006 · AI · contact PI
Core--Virology Facility$165,388
P01 · FY2006 · AI · contact PI
PPG: HOST VIRUS INTERACTIONS IN HCoV-SARS INFECTIONS$1,438,128
P01 · FY2005 · AI
Development of Murine Model for SARS-CoV Pathogenesis$279,892
P01 · FY2005 · AI
Role of CTL escape mutants in MHV-induced demyelination$244,435
R01 · FY2005 · NS
Core--Virology Facility$160,692
P01 · FY2005 · AI
PPG: HOST VIRUS INTERACTIONS IN HCoV-SARS INFECTIONS$1,466,243
P01 · FY2004 · AI
Development of Murine Model for SARS-CoV Pathogenesis$285,365
P01 · FY2004 · AI
Role of CTL escape mutants in MHV-induced demyelination$244,435
R01 · FY2004 · NS
Core--Virology Facility$163,833
P01 · FY2004 · AI
IMMUNOPATHOGENESIS OF VIRUS-INDUCED DEMYELINATION$257,250
R01 · FY2003 · NS
Role of CTL escape mutants in MHV-induced demyelination$244,435
R01 · FY2003 · NS
IMMUNOPATHOGENESIS OF VIRUS-INDUCED DEMYELINATION$257,250
R01 · FY2002 · NS
Role of CTL escape mutants in MHV-induced demyelination$244,388
R01 · FY2002 · NS
IMMUNOPATHOGENESIS OF VIRUS-INDUCED DEMYELINATION$257,250
R01 · FY2001 · NS
IMMUNOPATHOGENESIS OF VIRUS-INDUCED DEMYELINATION$257,250
R01 · FY2000 · NS
CTL ESCAPE MUTANTS AND MHV-INDUCED DEMYELINATION$177,153
R01 · FY2000 · NS
ANTIGEN SPECIFIC T CELLS IN INFLAMED CNS$73,500
R03 · FY2000 · AI